Voyager Reports Second Quarter 2025 Financial and Operating Results

What impact will this have on the company’s debt and equity structure? What are the long‑term implications for revenue growth and profitability? How might this news affect analyst coverage, target prices, and earnings estimates? What specific clinical data read‑outs are expected, and when will they be released? How does the Q2 2025 performance compare to prior quarters and consensus expectations? How does the extended runway change the company’s projected dilution or future financing needs? What are the key risks that could prevent the anticipated clinical data read‑outs from occurring? How does Voyager’s cash runway and clinical timeline compare to its competitors? What were the primary drivers that enabled the cash runway to be extended? What is the expected short‑term impact on the stock price following this release? How does the cash runway extension into 2028 affect Voyager's valuation and risk profile?